This is demonstrated by a completed phase 1 trial investigating the manufacturing feasibility and safety of CD19/CD22 bivalent CAR T cell therapy to treat B-ALL and LBCL (NCT03233854). This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.